What are the Challenges Associated with DAAs in Pediatrics?
Despite their benefits, there are several challenges associated with the use of DAAs in children:
1. Limited Clinical Trials: Most clinical trials for DAAs have been conducted in adults, with fewer studies specifically focusing on pediatric populations. 2. Dosing and Safety: Determining the appropriate dosing for children, who have different pharmacokinetics and pharmacodynamics compared to adults, can be challenging. 3. Drug Resistance: There is a potential for the development of resistance if the virus mutates, which could limit the effectiveness of DAAs. 4. Cost: DAAs are often expensive, which can be a barrier to access for some families.
